. 2021 Jul 6;28(3):164–172. doi: 10.1016/j.pulmoe.2021.06.009

Table 2.

Results of the base-case analysis (with and without confirmation by external RT-PCR).

Base-Case Analysis	Comparators	Mean Cost Per Patient (€)	Incremental Cost (€) ^*	Absolute Cost Savings (€)
a) with confirmation by external RT-PCR
COVID-19 patients prior to hospitalisation	Sofia SARS Antigen FIA®	−20.36	0	−20.36
COVID-19 patients prior to hospitalisation	Conventional approach	192.21	212.57
b) without confirmation by external RT-PCR

Base-Case Analysis	Comparators	Mean Cost Per Patient (€)	Incremental Cost (€)^*	Absolute Cost Savings (€)
COVID-19 patients prior to hospitalisation	Sofia SARS Antigen FIA®	37.96	0	–
COVID-19 patients prior to hospitalisation	Conventional approach	192.21	154.25

^⁎

Incremental cost denotes the increase in total costs resulting from using the conventional approach alone versus POCT.